EURETINA

The investigators explained that elevated angle-closure-related intraocular pressure may aggregate the visual impairment in patients with retinitis pigmentosa.

The Phase 2 Altitude study is an open-label, randomized, controlled, dose-escalation evaluation of RGX-314, evaluating the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in patients with moderately severe/severe non-proliferative diabetic retinopathy or mild proliferative diabetic retinopathy.

European investigators describe how they address complications associated with silicone oil endotamponade in vitreoretinal surgery.

Patients with RP experience greater levels of stress and anxiety than individuals in the general population and that the level of stress can be measured easily and non-invasively in hair.

Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.

Results from our recent poll regarding EURETINA 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the annual Congress in person in Hamburg, Germany.

The contest will take place as part of World Retina Day, Saturday, September 3, from 8:30-9:30 CEST in Hall X2/Channel 7.

The stated core foundation of the Women in Retina program is that “the best innovations happen when diverse people with different perspectives collaborate.” The program will help ESRS harness these perspectives and challenge the way things are done and allow for them to be done better.

A poll for retina specialists across the globe as the EURETINA 2022 meeting approaches. This poll is now closed.

This year’s hybrid meeting will allow attendees to participate in person or virtually. Either way, this congress will offer a wealth of information to specialists covering all aspects of retinal diseases.

A synopsis of the findings presented at EURETINA 2021 for ophthalmologists and retina specialists.

Tunde Peto, MD, PhD, discusses her presentation on providing the best virtual care for patients with diabetic eye disease at EURETINA 2021.

During a presentation at the EURETINA 2021 Virtual Congress, Prof. Ben Burton detailed how dry AMD patients treated with photobiomodulation therapy have seen improvements in best-corrected visual acuity 9 months after treatment.

In a presentation at the EURETINA 2021 Virtual Conference, Tunde Peto, MD, PhD, pointed out that while complications associated with diabetes develop over a long period, ophthalmologists today have an excellent understanding of diabetes-related eye changes.

During a presentation at the EURETINA 2021 Virtual Congress, Daniel Jones, PhD, discussed GA and emphasized the need for additional study to gain a better understanding of the burden experienced by patients.

In a presentation at the EURETINA 2021 Virtual Congress, Cristina Cristian, MD, noted that an injection of brolucizumab treatment in patients with neovascular age-related macular degeneration led to a median improvement in visual acuity (VA) of 10.5 letters and the drug was well-tolerated.

Dr. Ramin Tadayoni discusses the myopia panel at the EURETINA 2021 virtual meeting.

Grazia Pertile, MD, discusses the highlights of her presentations on the management of retinal folds after retinal detachment and the role of the anterior vitreous as a cause of recurrent retinal detachment.

During a presentation at the EURETINA 2021 Virtual Congress, Anat Loewenstein, MD, MHA, discussed how artificial intelligence can optimize optical coherence tomography.

During a presentation at the EURETINA 2021 Virtual Congress, José-Alain Sahel, MD, explains that optogenetics involves the use of artificial photoreceptors from specific retinal cells to restore vision by transferring a gene that encodes for a light-sensitive protein that causes neuronal cells to respond to light stimulation.

Carel B. Hoyng, MD, discusses his presentation regarding macula dystrophies, including Stargardt disease, Best disease, X-linked retinoschisis, and the peripherin-2 (PRPH2) gene.

Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.

Quan Dong Nguyen, MD, MSc, FARVO, FASRS, speaks on the highlights of his presentation regarding new biological treatments of posterior uveitis.

Jennifer Sun, MD, MPH, explores the question of whether ophthalmologists should be using anti-VEGF agents to treat patients with nonproliferative diabetic retinopathy (NPDR).

Treating the disease can be a challenge, and at the EURETINA 2021 Virtual Congress, Chekitaan Singh, MD, discussed a case study detailing the care of a patient who had already lost vision in one eye from a similar issue.

Speaking during the EURETINA 2021 Virtual Congress, Marta Belmonte-Grau, MD, discussed the potential risk for posterior capsular rupture during cataract surgery.

A poll for retina specialists across the globe as the EURETINA 2021 virtual meeting approaches.

Programming includes 16 EURETINA sessions; 22 symposia; 44 instructional courses; 85 hours of content, and more than 300 speakers.

The EURETINA 2021 Virtual Meeting is scheduled for September 9 to 12, 2021, and retina specialists eagerly await the showcase of cutting-edge scientific developments.

Euan S. Thomson, PhD, global president of ophthalmic devices at Carl Zeiss Meditec, talks about the “Zeiss Virtual Experience” during the 2020 EURETINA virtual meeting, and how attendees can navigate the booth to find the must-see products Zeiss is highlighting.